Impact LA-PDAC Tx w/Padeliporfin VTP

Cancer
Nadine Abi-Jaoudeh
A Phase I Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Padeliporfin Vascular Targeted Photodynamic Therapy for Patients with Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Pancreas

Study Description

This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the superior mesenteric artery (SMA) in patients with stage III, locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.

Eligibility

  • Patient is 18 years of age and older
  • Patients with a diagnosis of Stage III pancreatic ductal adenocarcinoma, cytologically or histologically confirmed
  • Patients have an unresectable tumor, evaluated as Stage III according to National Comprehensive Cancer Network (NCCN) guidelines resectability criteria, based on radiographic imaging or exploratory surgery as a locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
  • Patients with metastatic (stage IV) disease
  • Patients with previous radiotherapy treatment for pancreatic cancer
  • Patients who are pregnant and/or nursing
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.